AU4297297A - Pharmaceutical composition containing a 5HT2c antagonist and a D2 antagonist - Google Patents

Pharmaceutical composition containing a 5HT2c antagonist and a D2 antagonist

Info

Publication number
AU4297297A
AU4297297A AU42972/97A AU4297297A AU4297297A AU 4297297 A AU4297297 A AU 4297297A AU 42972/97 A AU42972/97 A AU 42972/97A AU 4297297 A AU4297297 A AU 4297297A AU 4297297 A AU4297297 A AU 4297297A
Authority
AU
Australia
Prior art keywords
antagonist
pharmaceutical composition
composition containing
5ht2c
5ht2c antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU42972/97A
Other versions
AU725817B2 (en
Inventor
Thomas Paul Blackburn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of AU4297297A publication Critical patent/AU4297297A/en
Application granted granted Critical
Publication of AU725817B2 publication Critical patent/AU725817B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
AU42972/97A 1996-07-26 1997-07-22 Pharmaceutical composition containing a 5HT2c antagonist and a D2 antagonist Ceased AU725817B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9615767 1996-07-26
GBGB9615767.2A GB9615767D0 (en) 1996-07-26 1996-07-26 Novel treatment
PCT/EP1997/004159 WO1998004289A2 (en) 1996-07-26 1997-07-22 Pharmaceutical composition containing a 5ht2c antagonist and a d2 antagonist

Publications (2)

Publication Number Publication Date
AU4297297A true AU4297297A (en) 1998-02-20
AU725817B2 AU725817B2 (en) 2000-10-19

Family

ID=10797573

Family Applications (1)

Application Number Title Priority Date Filing Date
AU42972/97A Ceased AU725817B2 (en) 1996-07-26 1997-07-22 Pharmaceutical composition containing a 5HT2c antagonist and a D2 antagonist

Country Status (19)

Country Link
EP (1) EP0936924A2 (en)
JP (1) JP2000516924A (en)
KR (1) KR20000029564A (en)
CN (1) CN1230894A (en)
AR (1) AR008083A1 (en)
AU (1) AU725817B2 (en)
BR (1) BR9710568A (en)
CA (1) CA2261813A1 (en)
CO (1) CO5031292A1 (en)
CZ (1) CZ23799A3 (en)
GB (1) GB9615767D0 (en)
HU (1) HUP9903619A3 (en)
IL (1) IL128219A0 (en)
NO (1) NO990322L (en)
NZ (1) NZ333813A (en)
PL (1) PL331426A1 (en)
TR (1) TR199900140T2 (en)
WO (1) WO1998004289A2 (en)
ZA (1) ZA976593B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9612883D0 (en) * 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds
EP1135136B1 (en) * 1998-11-23 2003-11-05 Sepracor Inc. Pharmaceutical compositions containing olanzapine-n-oxide
ATE286398T1 (en) 1998-11-23 2005-01-15 Sepracor Inc COMPOSITIONS AND METHODS CONTAINING DESMETHYLOLANZAPINE
CA2352611A1 (en) 1998-11-23 2000-06-02 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
JP2003525865A (en) 1999-03-18 2003-09-02 チルドレンズ・ホスピタル・リサーチ・ファウンデイション Treatment of bulimia nervosa and related eating disorders by administration of atypical antipsychotics
CA2363784A1 (en) * 1999-05-19 2000-11-30 Astrazeneca Ab Method of treatment
WO2005013969A1 (en) * 2003-07-15 2005-02-17 Janssen Pharmaceutica N.V. Antipsychotic agent with socializing properties

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9500998D0 (en) * 1995-03-19 1995-03-19 Haakan Wilhelm Wikstroem New sulfone ester analogues of iso-clozapine and related structures: atypical neuroleptics

Also Published As

Publication number Publication date
HUP9903619A3 (en) 2001-03-28
NZ333813A (en) 2000-07-28
CN1230894A (en) 1999-10-06
IL128219A0 (en) 1999-11-30
WO1998004289A2 (en) 1998-02-05
ZA976593B (en) 1999-01-25
KR20000029564A (en) 2000-05-25
BR9710568A (en) 1999-08-17
NO990322L (en) 1999-03-24
JP2000516924A (en) 2000-12-19
CA2261813A1 (en) 1998-02-05
CO5031292A1 (en) 2001-04-27
PL331426A1 (en) 1999-07-19
TR199900140T2 (en) 1999-03-22
AU725817B2 (en) 2000-10-19
CZ23799A3 (en) 1999-06-16
EP0936924A2 (en) 1999-08-25
HUP9903619A2 (en) 2000-10-28
NO990322D0 (en) 1999-01-25
AR008083A1 (en) 1999-12-09
GB9615767D0 (en) 1996-09-04
WO1998004289A3 (en) 1998-03-19

Similar Documents

Publication Publication Date Title
AUPN605795A0 (en) Analgesic pharmaceutical composition
AU1618697A (en) Novel compounds and pharmaceutical use thereof
HU9601698D0 (en) Pharmaceutical composition
AUPN411195A0 (en) Medicinal composition
AU4407797A (en) Pharmaceutical composition forming a gel
GB9519667D0 (en) Pharmaceutical composition
ZA962214B (en) Pharmaceutical composition
ZA963590B (en) Pharmaceutical composition
IL118142A (en) Pharmaceutical composition containing tiagabine hydrochloride together with antioxidants and its preparation
AU6422298A (en) Pharmaceutical composition containing a phosphorylamide and an ayntibiotic
AU4297297A (en) Pharmaceutical composition containing a 5HT2c antagonist and a D2 antagonist
GB9525194D0 (en) Pharmaceutical composition
GB9502695D0 (en) Pharmaceutical composition
ZA964193B (en) Pharmaceutical composition
AU7681498A (en) Pharmaceutical composition and use thereof
HU9602822D0 (en) Pharmaceutical composition
ZA963591B (en) Pharmaceutical composition
ZA95736B (en) Pharmaceutical composition
AU741226C (en) Pharmaceutical composition
AU723097C (en) Pharmaceutical composition
ZA963388B (en) A pharmaceutical composition
AUPM359094A0 (en) A pharmaceutical composition
GB9519748D0 (en) Pharmaceutical composition
GB9505368D0 (en) Pharmaceutical composition
HU9903430D0 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired